Tara O Brien
About Tara O Brien
Tara O'Brien is a Manager of Managed Services at IntegriChain, where she has worked since 2017. With over ten years of experience in the pharmaceutical industry, she specializes in commercial and government contracts.
Work at IntegriChain
Tara O'Brien has been employed at IntegriChain since 2017, serving as the Manager of Managed Services. In this role, she oversees various aspects of managed services, contributing to the company's operations in Philadelphia, Pennsylvania. Her tenure at IntegriChain spans over seven years, during which she has utilized her expertise in the pharmaceutical industry to enhance service delivery and client satisfaction.
Previous Experience in the Pharmaceutical Industry
Before joining IntegriChain, Tara O'Brien worked at several organizations within the pharmaceutical sector. She served as an Analyst in government contracting at Sanofi from 2013 to 2015. Following this, she held the position of Business Analyst at iContracts, Inc. from 2015 to 2017. Additionally, she worked at Bracco as a GPO and Rebate Coordinator from 2008 to 2013. This diverse experience has provided her with a solid foundation in commercial and government contracts.
Education and Expertise
Tara O'Brien possesses over ten years of experience in the pharmaceutical industry, with a specialization in areas such as Medicaid, Rebates, Group Purchasing Organizations (GPO), GPO memberships, Nuclear Medicine, and accruals. Her knowledge and skills in these areas have been developed through her various roles in the industry, allowing her to effectively manage complex projects and contracts.
Background in Government Contracting
Tara O'Brien's background includes significant experience in government contracting, particularly during her time at Sanofi. Her role as an Analyst involved navigating the complexities of government contracts, which has been a critical component of her career. This experience has equipped her with the necessary skills to manage and analyze contracts effectively within the pharmaceutical landscape.